HOME > 아카이브 > 미디어허브(영문)
Kainos Medicine, spearheaded by CEO Lee Ki-seop and renowned for its prowess in drug development, recently declared the successful culmination of its Phase 3 clinical trial for ACC008, an AIDS treatment medication. This trial was executed in China, in collaboration with their Chinese affiliate, Jiangsu Aidea, aimed at broadening market outreach.
This clinical trial holds immense significance as it’s a comprehensive study that benchmarks ACC008 against Genvoya, a medication formulated by Gilead. The study also validates that ACC008 can be an alternative for patients who have been on different treatments.
The trial, undertaken with 757 patients across 10 prominent clinical centers, including the Beijing Ditan Hospital linked with Capital Medical University, confirmed ACC008’s non-inferiority, effectiveness, and safety to Genvoya. Furthermore, it sustained viral suppression for an impressive 48 weeks.
ACC008 amalgamates three potent drugs: KM-023, TDF, and 3C3. In December 2022, the drug won approval (branded ‘Fubangde’, active ingredient ‘Ainuomiti’) from the Chinese Food and Drug Administration, cementing its reputation as an established anti-HIV treatment in China.
Following the guidelines set by the Chinese Center for Drug Evaluation (CDE), this Phase 3 trial utilized a randomized, double-blind structure targeting patients familiar with existing treatments. Moreover, a comparative non-inferiority test was executed against Genvoya, an AIDS medication covered by Chinese health insurance. ACC008’s clinical outcomes highlighted its potential to supersede other anti-HIV medications, facilitating enhanced patient compliance and elevating treatment outcomes and safety.
Once greenlighted for an extended patient demographic, ACC008 stands to offer a groundbreaking treatment alternative for AIDS patients resistant to conventional medications or those experiencing diminished treatment efficacy. This nod of approval could catapult ACC008 not just in the Chinese domain but on a global scale.
A spokesperson for Kainos Medicine elaborated, “The distinctive benefits of ACC008, as showcased in this trial, positions it to potentially dominate global markets, encompassing European territories and economically challenged nations. This past April, our international tech transfer agreement for our AIDS medication promises a surge in royalty sales.”
Kainos Medicine, stationed at Korea Bio Park in Pangyo Techno Valley, Seongnam-si, is a global pharma trailblazer, delving into novel drug innovations targeting brain disorders, cancer, and infectious ailments.